Trial Profile
Open, Non Controlled, Multicenter, First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Murlentamab (Primary) ; Carboplatin; Paclitaxel
- Indications Cervical cancer; Endometrial cancer; Gynaecological cancer; Ovarian cancer
- Focus Adverse reactions; First in man
- Sponsors GamaMabs Pharma
- 27 Mar 2022 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Results (n=68) presented at the 55th Annual Meeting of the American Society of Clinical Oncology